Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;59(2):383-9.
doi: 10.1007/s10620-013-2900-x. Epub 2013 Oct 15.

Third-line Rescue Therapy With Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (With Clarithromycin and Levofloxacin) for H. Pylori Infection

Affiliations
Clinical Trial

Third-line Rescue Therapy With Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (With Clarithromycin and Levofloxacin) for H. Pylori Infection

J P Gisbert et al. Dig Dis Sci. .

Abstract

Background: Helicobacter pylori eradication therapy with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin fails in >20 % of cases. A rescue therapy with PPI-amoxicillin-levofloxacin still fails in >20 % of patients.

Aim: To evaluate the efficacy and tolerability of a bismuth-containing quadruple regimen in patients with two consecutive eradication failures.

Methods: Prospective multicenter study of patients in whom 1st treatment with PPI-clarithromycin-amoxicillin and 2nd with PPI-amoxicillin-levofloxacin had failed. A 3rd eradication regimen with a 7- to 14-day PPI (standard dose b.i.d.), bismuth subcitrate (120 mg q.i.d. or 240 mg b.i.d.), tetracycline (from 250 mg t.i.d. to 500 mg q.i.d.) and metronidazole (from 250 mg t.i.d. to 500 mg q.i.d.). Eradication was confirmed by (13)C-urea-breath-test 4-8 weeks after therapy. Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated by means of a questionnaire.

Results: Two hundred patients (mean age 50 years, 55 % females, 20 % peptic ulcer/80 % uninvestigated-functional dyspepsia) were initially included, and two were lost to follow-up. In all, 97 % of patients complied with the protocol. Per-protocol and intention-to-treat eradication rates were 67 % (95 % CI 60-74 %) and 65 % (58-72 %). Adverse effects were reported in 22 % of patients, the most common being nausea (12 %), abdominal pain (11 %), metallic taste (8.5 %), and diarrhea (8 %), none of them severe.

Conclusion: A bismuth-containing quadruple regimen is an acceptable third-line strategy and a safe alternative after two previous H. pylori eradication failures with standard clarithromycin- and levofloxacin-containing triple therapies.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. BMC Gastroenterol. 2007 Jul 25;7:31 - PubMed
    1. Aliment Pharmacol Ther. 2003 May 1;17(9):1137-43 - PubMed
    1. Aliment Pharmacol Ther. 2003 Feb 15;17(4):553-60 - PubMed
    1. Korean J Gastroenterol. 2004 Sep;44(3):136-41 - PubMed
    1. Helicobacter. 2011 Aug;16(4):289-94 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback